Solutions by industry · Pharmaceuticals
New products, manufacturing capacity, compliance, technology and facility investments create complex capital decisions years before their full impact is known. Weissr helps pharmaceutical companies compare competing investment needs, allocate capital across sites and maintain governance from strategic planning through execution.
In short
Capex planning in pharmaceutical manufacturing means making long-term investment decisions in an environment where demand, product mix and regulatory requirements can all change before new capacity is ready.
02 · Capital before certainty
Capital decisions may need to be made while future demand, product mix, regulatory requirements and capacity needs are still evolving, against limited capital and changing assumptions.
The recurring challenge pharma leaders describe is not a lack of capital discipline, but building the business case that convinces management and the board to commit capital years ahead of demand.
Multi-site manufacturers often manage capital requests through large, manually maintained spreadsheets with dozens of fields per project.
Teams compare successive forecast snapshots against each other just to see how far the plan has drifted, which consumes time better spent on the investment decision itself.
03 · Site scenarios
Available capacity, expansion, new production technology and greenfield investment are modelled as alternatives to one another, not evaluated site by site.
04 · Capex Strategy
Model capacity scenarios across the manufacturing network, including existing capacity, site expansion, new technology or a greenfield build, with explicit assumptions about demand, product mix and timing, so the board sees the reasoning behind the commitment.
05 · Capex Management
Global investment governance, local execution: one standardised investment framework while individual plants and business units manage their own requirements, from request and approval to forecast, execution and portfolio visibility.
06 · R&D-to-production network
Capacity scenarios across sites are compared against pipeline-driven demand and the capital actually available.
Pipeline / NPI
Demand signal and launch timing
Site A
Available capacity, investment requirement
Site B
Expansion option
Site C
New production technology
Greenfield
New site investment alternative
Compliance & quality
Mandatory capital requirement
Weissr capital portfolio
One optimal capital path across the site network
One platform for the capital cycle
Software solution
Decide where capital should go.
Model long-term investment alternatives across the entire asset portfolio and understand which path creates the greatest long-term value.
Add-on module for Capex Management
Turn strategic priorities into capital allocation.
Reconcile strategic direction with bottom-up investment demand and allocate budgets across the organisation.
Software solution
Control what happens next.
Manage requests, budgets, approvals, forecasts and investment follow-up in one governed environment.
Capex outcomes
Strategic
Capacity decisions are taken across the network rather than site by site, so the question is where the volume should sit, not which site asked first.
Financial
Capital is protected from being committed to the wrong site or at the wrong moment.
Operational
One governed framework replaces spreadsheet-based request tracking and manual forecast-snapshot comparison.
$700B+
Value of assets analysed in Weissr
1,000+
Production sites globally
ISO 27001
Certified information security
Enterprise-grade security and governance across every deployment
Capex Maturity Assessment
Answer a short set of questions on process, data, visibility and cash flow, and get a report showing your level in each area.
Take the assessmentCapex explained
Capex planning in pharmaceutical manufacturing means making long-term investment decisions in an environment where demand, product mix and regulatory requirements can all change before new capacity is ready.
Companies need to compare options across sites, from expanding existing capacity and upgrading technology to building new facilities, while accounting for the realities of a highly regulated GMP environment. Validation, qualification and regulatory requirements can add significant time and cost to an investment and need to be considered from the start.
Site decisions are also shaped by access to specialised skills in areas such as quality, validation and process engineering. The ability to attract and retain the right people can materially affect how quickly capacity comes online and how well an investment performs over time.
Good Capex planning brings these factors together on one financial basis, so leadership can compare scenarios consistently and make investment decisions that remain robust despite uncertainty.
By modelling each site’s realistic options, including available capacity, expansion and new technology, alongside a greenfield alternative and comparing them on one financial basis, including qualification timelines, risk and the consequences of demand arriving earlier or later than forecast.
Because construction, qualification and regulatory approval mean new capacity can take years to become usable. Waiting for demand certainty would mean arriving late, so capital is committed while assumptions are still evolving.
Weissr structures the case around explicit alternatives, cash-flow profiles, timing and strategic criteria, and keeps the assumptions and decision history attached to the investment, which is what board and management review typically asks for.
Global governance sets one standardised framework for how investments are requested, evaluated, approved and reported so the portfolio is comparable. Local execution leaves plants and business units responsible for defining and delivering their own investments within that framework.
Compliance capital should be modelled explicitly as its own portfolio category so its true size is visible, leaving a clear picture of the discretionary capital available for capacity and growth rather than treating compliance as an unexamined deduction.
It puts both options on the same footing across capital profile, time to qualified capacity, operating cost and flexibility, and compares them on the cash flow of the company as a whole. Demand, price and approval timing are then varied, so the choice rests on which option holds up across outcomes rather than on a single base case.
One governed record per investment, with owners updating timing and expected spend in the same place actuals are connected, removes manual snapshot comparison and makes forecast drift visible as it happens.
